Cancer Drug Shop BioVex Markets Legacy Technology for shRNA Delivery
April 15, 2010
Cancer Drug Shop BioVex Markets Legacy Technology for shRNA Delivery
The technology comprises replication-defective herpes simplex viruses that express shRNAs and can be delivered to the nervous system both in vitro and in vivo, and the company has been marketing it for research applications.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With AAV Technology in the Clinic, NanoCor Aims to Develop shRNA-Based Heart Failure Drug
April 4, 2013 / Gene Silencing News - Mass. Court Dismisses CSHL Lawsuit Against Former IP Counsel
March 21, 2013 / Gene Silencing News - University of Amsterdam Team Identifies Argonaute as Key to Dicer-Independent shRNA Processing
February 14, 2013 / Gene Silencing News - Q&A: City College's Kevin Ryan on Circularized Oligos for Small RNA Generation in Human Cells
January 3, 2013 / Gene Silencing News - As Sigma-Aldrich Fights Sales Data Subpoena, CSHL Argues that Information Will be Anonymous
December 20, 2012 / Gene Silencing News